Found: 240
Select item for more details and to access through your institution.
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
- Published in:
- BMC Infectious Diseases, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12879-024-09300-5
- By:
- Publication type:
- Article
Monoclonal antibodies targeting sites in respiratory syncytial virus attachment G protein provide protection against RSV-A and RSV-B in mice.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-47146-2
- By:
- Publication type:
- Article
Formulary Drug Reviews: Nirsevimab.
- Published in:
- Hospital Pharmacy, 2024, v. 59, n. 2, p. 138, doi. 10.1177/00185787231212620
- By:
- Publication type:
- Article
Respiratory Morbidity in Prematurely Born Children Receiving Palivizumab Prophylaxis of Respiratory Syncytial Virus Disease.
- Published in:
- Iranian Journal of Neonatology, 2024, v. 15, n. 2, p. 3, doi. 10.22038/ijn.2024.76446.2482
- By:
- Publication type:
- Article
National Coalition for Infant Health: Respiratory Syncytial Virus Prevention Options.
- Published in:
- Neonatology Today, 2024, v. 19, n. 4, p. 83
- By:
- Publication type:
- Article
An epidemiological investigation of high-risk infants for Respiratory Syncytial Virus infections: a retrospective cohort study.
- Published in:
- Italian Journal of Pediatrics, 2024, v. 50, n. 1, p. 1, doi. 10.1186/s13052-024-01627-8
- By:
- Publication type:
- Article
Balanced on the Biggest Wave: Nirsevimab for Newborns.
- Published in:
- Neonatal Network, 2024, v. 43, n. 2, p. 105, doi. 10.1891/NN-2023-0056
- By:
- Publication type:
- Article
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date.
- Published in:
- Pediatric Drugs, 2024, v. 26, n. 2, p. 101, doi. 10.1007/s40272-023-00606-6
- By:
- Publication type:
- Article
Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro.
- Published in:
- Turkish Journal of Pediatrics, 2024, v. 66, n. 2, p. 161, doi. 10.24953/turkjpediatr.2024.4592
- By:
- Publication type:
- Article
Efficacy of Palivizumab Immunoprophylaxis for Reducing Severe RSV Outcomes in Children with Immunodeficiencies: A Systematic Review.
- Published in:
- Journal of the Pediatric Infectious Diseases Society, 2024, v. 13, n. 2, p. 136, doi. 10.1093/jpids/piae004
- By:
- Publication type:
- Article
Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus.
- Published in:
- Molecules, 2024, v. 29, n. 3, p. 598, doi. 10.3390/molecules29030598
- By:
- Publication type:
- Article
Protecting Infants from RSV: Understanding Guidance on New Prevention Tools.
- Published in:
- Neonatology Today, 2023, v. 18, n. 12, p. 12
- By:
- Publication type:
- Article
Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus Infection in Very Preterm Infants in the First Year of Life in The Netherlands.
- Published in:
- Vaccines, 2023, v. 11, n. 12, p. 1807, doi. 10.3390/vaccines11121807
- By:
- Publication type:
- Article
Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 11, p. 2276, doi. 10.3390/v15112276
- By:
- Publication type:
- Article
Respiratory syncytial virus and its prophylaxis with palivizumab: exploring nurses' knowledge.
- Published in:
- Nursing Children & Young People, 2023, v. 35, n. 5, p. 14, doi. 10.7748/ncyp.2023.e1458
- By:
- Publication type:
- Article
Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease.
- Published in:
- Drug, Healthcare & Patient Safety, 2023, v. 15, p. 103, doi. 10.2147/DHPS.S348727
- By:
- Publication type:
- Article
Potential Benefits of Expanded Palivizumab in American Indian Children Under the Age of 2 Years.
- Published in:
- Journal of the Pediatric Infectious Diseases Society, 2023, v. 12, n. 9, p. 522, doi. 10.1093/jpids/piad063
- By:
- Publication type:
- Article
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks' gestational age.
- Published in:
- PLoS ONE, 2023, v. 18, n. 9, p. 1, doi. 10.1371/journal.pone.0289828
- By:
- Publication type:
- Article
Prévention du virus respiratoire syncitial (VRS) chez les nourrissons : une petite révolution ?
- Published in:
- Médecine Thérapeutique: Pédiatrie, 2023, v. 25, n. 3/4, p. 172, doi. 10.1684/mtp.2023.0783
- By:
- Publication type:
- Article
Hospitalization for bronchiolitis in children aged ≤ 1year, Southern Italy, year 2021: need for new preventive strategies?
- Published in:
- Italian Journal of Pediatrics, 2023, v. 49, n. 1, p. 1, doi. 10.1186/s13052-023-01455-2
- By:
- Publication type:
- Article
Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 5, p. 1067, doi. 10.3390/v15051067
- By:
- Publication type:
- Article
Target Trial Emulation and Bias Through Missing Eligibility Data: An Application to a Study of Palivizumab for the Prevention of Hospitalization Due to Infant Respiratory Illness.
- Published in:
- American Journal of Epidemiology, 2023, v. 192, n. 4, p. 600, doi. 10.1093/aje/kwac202
- By:
- Publication type:
- Article
New Developments and Challenges in Antibody-Based Therapies for the Respiratory Syncytial Virus.
- Published in:
- Infection & Drug Resistance, 2023, v. 16, p. 2061, doi. 10.2147/IDR.S379660
- By:
- Publication type:
- Article
Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02792-z
- By:
- Publication type:
- Article
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 2, p. e230023, doi. 10.1001/jamanetworkopen.2023.0023
- By:
- Publication type:
- Article
Home Immunization with Palivizumab-A Randomized Pilot Study Describing Safety Aspects and Parents' Preferences.
- Published in:
- Children, 2023, v. 10, n. 2, p. 198, doi. 10.3390/children10020198
- By:
- Publication type:
- Article
Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study: Palivizumab prophylaxis in children with congenital heart disease.
- Published in:
- Italian Journal of Pediatrics, 2023, v. 49, n. 1, p. 1, doi. 10.1186/s13052-022-01399-z
- By:
- Publication type:
- Article
Briefly Legal: Should a Six-Week Old Infant with Respiratory Syncytial Virus be Admitted to a Pediatric Ward?
- Published in:
- Neonatology Today, 2022, v. 17, n. 12, p. 34, doi. 10.51362/neonatology.today/202217123438
- By:
- Publication type:
- Article
Characterisation of RSV Fusion Proteins from South African Patients with RSV Disease, 2019 to 2020.
- Published in:
- Viruses (1999-4915), 2022, v. 14, n. 11, p. 2321, doi. 10.3390/v14112321
- By:
- Publication type:
- Article
A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice.
- Published in:
- Biomedicines, 2022, v. 10, n. 10, p. N.PAG, doi. 10.3390/biomedicines10102516
- By:
- Publication type:
- Article
МОНОКЛОНАЛНИ АНТИТЕЛА В ПЕДИАТРИЯТА.
- Published in:
- Medical Review / Meditsinski Pregled, 2022, v. 58, n. 5, p. 19
- By:
- Publication type:
- Article
The spread and symptoms of respiratory syncytical virus.
- Published in:
- African Journal of Respiratory Medicine, 2022, v. 17, n. 8, p. 8, doi. 10.54931/1747-5597.22.17.39
- By:
- Publication type:
- Article
Summary of the National Advisory Committee on Immunization (NACI) statement update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants.
- Published in:
- Canada Communicable Disease Report, 2022, v. 48, n. 7/8, p. 363, doi. 10.14745/ccdr.v48i78a08
- By:
- Publication type:
- Article
It Was Worse Than Open-Heart Surgery.
- Published in:
- Neonatology Today, 2022, v. 17, n. 6, p. 113, doi. 10.51362/neonatology.today/2022176113115
- By:
- Publication type:
- Article
RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.880368
- By:
- Publication type:
- Article
Protein and Peptide Substances in the Treatment of Respiratory Syncytial Infection: Current State.
- Published in:
- Molecules, 2022, v. 27, n. 7, p. 2263, doi. 10.3390/molecules27072263
- By:
- Publication type:
- Article
Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 3, p. 1246, doi. 10.1111/bcp.15069
- By:
- Publication type:
- Article
Risk factors for hospitalisation due to respiratory syncytial virus infection in children receiving prophylactic palivizumab.
- Published in:
- European Journal of Pediatrics, 2022, v. 181, n. 2, p. 539, doi. 10.1007/s00431-021-04216-7
- By:
- Publication type:
- Article
Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
- Published in:
- European Journal of Pediatrics, 2022, v. 181, n. 2, p. 841, doi. 10.1007/s00431-021-04233-6
- By:
- Publication type:
- Article
Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?
- Published in:
- Breathe, 2021, v. 17, n. 4, p. 1, doi. 10.1183/20734735.0110-2021
- By:
- Publication type:
- Article
The National Paediatric Medicines Forum: Who we are and what are we doing.
- Published in:
- Journal of Paediatrics & Child Health, 2021, v. 57, n. 12, p. 2022, doi. 10.1111/jpc.15789
- By:
- Publication type:
- Article
Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia.
- Published in:
- Journal of Infection in Developing Countries, 2021, v. 15, n. 11, p. 1708, doi. 10.3855/jidc.12561
- By:
- Publication type:
- Article
Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs.
- Published in:
- BMC Pharmacology & Toxicology, 2021, v. 22, n. 1, p. 1, doi. 10.1186/s40360-021-00520-y
- By:
- Publication type:
- Article
Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab.
- Published in:
- Brazilian Journal of Pulmonology / Jornal Brasileiro de Pneumologia, 2021, v. 47, n. 5, p. 1, doi. 10.36416/1806-3756/e20210157
- By:
- Publication type:
- Article
Clinical Pearl: RSV(P): Will It Be Joining Us this Fall? Interim Guidance from the AAP for the Use of Pavalizumab Prophylaxis During the Delayed RSV Surge.
- Published in:
- Neonatology Today, 2021, v. 16, n. 9, p. 145, doi. 10.51362/neonatology.today/20219169145146
- By:
- Publication type:
- Article
Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities.
- Published in:
- Vaccines, 2021, v. 9, n. 9, p. 961, doi. 10.3390/vaccines9090961
- By:
- Publication type:
- Article
Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25265-4
- By:
- Publication type:
- Article
Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.708939
- By:
- Publication type:
- Article
Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-95150-z
- By:
- Publication type:
- Article
Does Prophylaxis Against Respiratory Syncytial ID Virus Infection Affect the Weight Percentiles of Infants with Hemodynamically Significant Congenital Heart Disease?
- Published in:
- Journal of Dr. Behcet Uz Children's Hospital, 2021, v. 11, n. 2, p. 174, doi. 10.5222/buchd.2021.60320
- By:
- Publication type:
- Article